|
Timo Joensuu (b. 27 February 1957 in Nokia, Finland) is a Finnish oncologist, associate professor of clinical oncology in University of Helsinki, researcher of new cancer treatments and developer of an internationally new hospital concept. He is a co-founder of Docrates Cancer Center in Helsinki and its clinical director since 2007. Dr Joensuu studied medicine in the University of Tampere. He graduated MBBS and qualified professional MD 1986 and presented his doctoral thesis on cytodifferentation in 1992. 1991–1993 he had a research fellowship in INSERM, Institut national de la santé et de la recherche médicale in Paris. Joensuu specialized in oncology, radio therapy and nuclear medicine in Helsinki University Hospital where he worked 1991-2007. He has also been medical advisor for AstraZeneca and for Helsinki Consulting Group and World Bank in Serbia year 2004. Since 2007 he is the clinical director of Docrates Cancer Center and member of the board of directors of the company. Dr Joensuu has led several clinical trials and published articles on oncolytic adenovirus therapy, radiotherapy, chemoradiotherapy and prostate cancer. Dr Joensuu was the first doctor in Nordic Countries to use IMRT (Intensity-modulated radiation therapy). In Docrates Cancer Center Dr Joensuu has developed a new private sector hospital concept, uniting a hospital, a health care hotel and integrated well-being services for the patients. At the same time the hospital participates clinical research and drug testing networking with universities and medibusiness. Dr Joensuus´s vision is a fast track path from diagnosis to treatment, founded on the belief that cancer care can be carried out different way compared to traditional models that can be considered slow and out-dated. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Timo Joensuu」の詳細全文を読む スポンサード リンク
|